Breaking Finance News

Angle PLC (LON:AGL) target price held steady at 100.00GBX, issued a report today by finnCap

Yesterday Angle PLC (LON:AGL) traded -3.60% lower at 36.25GBX. The company’s 50-day moving average is 41.24GBX and its 200-day moving average is 50.72GBX. The last closing price is down -33.95% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 769,276 shares of the stock were exchanged, up from an average trading volume of 272,799

Angle PLC (LON:AGL) had its target price hold steady to 100.00GBX by finnCap in a report released 9/13/2017. The new target price indicates a possible upside of 1.76% based on the company's last closing price.

Previously on 09/11/2017, finnCap reported on Angle PLC (LON:AGL) held steady the target price at 100.00GBX. At the time, this indicated a possible upside of 1.78%.

See Chart Below

Angle PLC (LON:AGL)

Angle PLC has a 52 week low of 32.27GBX and a 52 week high of 80.00GBX The company’s market cap is currently 0 GBX.

In addition to finnCap reporting its target price, a total of 1 broker has issued a report on the stock. The consensus target price is 200.00GBX with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Angle PLC (LON:AGL)

ANGLE plc is a holding company. The Company's principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. Its Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The resulting liquid biopsy (blood test) enables the detection and investigation of mutations in the patient's cancer for personalized cancer care. The harvested CTCs have a range of applications, including diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness and remission monitoring.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.